India, Sept. 8 -- Astec LifeSciences Q1 FY27 results show the company is slowly moving back to operating profitability. Standalone losses decreased to Rs. 18.74 Crore from Rs. 33.06 Crore a year earlier. The real reason the stock rose was that EBITDA became positive. Management's FY27 forecast says that CDMO will make up more than half of revenue giving a growth angle that investors had not fully priced in until Kotak's note was released today.

Shares of Astec Lifescience Ltd are trading at Rs. 662.80, up 20.00 percent on Tuesday. The stock touched the intraday high of Rs. 662.80 after opening at Rs. 551.20. The company commands a market capitalization of Rs. 1,476.91 crore.

Why Did the Stock Rally Today? Astec's rally comes down to a ...